Outsourcing facilities can continue to compound semaglutide injectable drugs until May 22, after which date the FDA may take action against them. Recently, a separate federal court ruled in favor of ...

In a world of custom solutions, medicine is no exception. Perhaps the most fascinating modern medical phenomenon is the growing popularity of the compounding pharmacy, a business committed to ...

The ruling also means the grace period for 503B outsourcing facilities to compound semaglutide injectable drugs will expire on May 22, 2025, and FDA may take enforcement action against these ...

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...

The FDA’s announcement hurt shares of the telehealth firm Hims & Hers (HIMS), which launched compounded versions of semaglutide last year at a sharp discount to the branded version. U.S ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy. A federal ...

Novo Nordisk sells semaglutide under the brands Wegovy and Ozempic for weight loss and type 2 diabetes treatment respectively. Image credit: Getty/UCG. A US judge has rejected efforts by a compounded ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run pharmacies must immediately stop making copies of the blockbuster drug. A Texas ...

In 2022, the FDA announced there was a shortage of the brand-name medications, which allowed compounding pharmacies to make generic semaglutide, the main active ingredient in the weight-loss drugs.

HPM: Another product in your portfolio, which uses the popular compound, Semaglutide ... dilution caused by offerings; conversion of outstanding shares of preferred stock and the rights and ...